FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2570289311> ?p ?o ?g. }

• W2570289311 endingPage "2497" @default.
• W2570289311 startingPage "2497" @default.
• W2570289311 abstract "Abstract Abstract 2497 Chromosomal translocations that affect the MLL (Mixed Lineage Leukemia) proto-oncogene occur in aggressive acute leukemias, both in children and adults. Fusion of MLL to one of more than 50 partner genes results in generation of the MLL fusion oncoprotein, which upregulates expression of HOX genes required for normal hematopoiesis, and ultimately leads to the development of acute leukemia. Patients harboring translocations of MLL gene suffer from very aggressive leukemias and respond poorly to available therapies, emphasizing the urgent need for novel therapeutic treatments. All oncogenic MLL fusion proteins have a preserved N-terminal fragment of MLL that interacts with menin, a tumor suppressor protein encoded by MEN1 (Multiple Endocrine Neoplasia 1) gene. Importantly, the menin-MLL fusion protein interaction is critical to the leukemogenic activity of MLL fusion proteins and misregulation of HOXA9 genes, and therefore it represents a valuable molecular target for therapeutic intervention. Selective targeting of the protein-protein interaction between menin and MLL fusion proteins with small molecules could block the oncogenic activity of MLL fusion proteins and inhibit development of acute leukemia. To identify small molecule inhibitors of the menin-MLL interaction we have performed a High Throughput Screen of 350,000 compounds using a collection of biochemical assays and biophysical methods. This resulted in several classes of compounds that specifically bind to menin and inhibit the menin-MLL interaction both in vitro and in human cells. We then applied medicinal chemistry approaches to develop analogues of selected lead candidates, resulting in very potent compounds that inhibit the menin-MLL interaction with nanomolar affinities. To evaluate potency, specificity and mechanism of action of these compounds we used a broad collection of cellular assays. These compounds selectively inhibit proliferation of the MLL leukemia cells, strongly induce apoptosis and differentiation of these cells. Importantly, these compounds substantially downregulate expression of HOXA9 and MEIS1 genes that are downstream targets of MLL fusion proteins required for their leukemogenicity, and they also deplete the menin-MLL fusion protein complex from the target genes. Furthermore, the compounds that we developed specifically inhibit the MLL fusion protein mediated oncogenic transformation. All these effects closely recapitulate the effects observed upon acute loss of menin or disruption of the menin-MLL fusion protein interaction using genetic manipulations, demonstrating highly specific mode of action for these compounds. Our current efforts are focused to assess the effect of these compounds in in vivo models of MLL leukemia and evaluate their utility as future drug candidates for acute leukemias. This may provide a novel therapeutic approach for the treatment of very aggressive leukemias with MLL translocations. Disclosures: No relevant conflicts of interest to declare." @default.
• W2570289311 created "2017-01-13" @default.
• W2570289311 creator A5008141260 @default.
• W2570289311 creator A5011317809 @default.
• W2570289311 creator A5026691889 @default.
• W2570289311 creator A5029035188 @default.
• W2570289311 creator A5044898715 @default.
• W2570289311 creator A5052716698 @default.
• W2570289311 creator A5069778809 @default.
• W2570289311 creator A5080373326 @default.
• W2570289311 creator A5080568394 @default.
• W2570289311 creator A5084249783 @default.
• W2570289311 date "2011-11-18" @default.
• W2570289311 modified "2023-10-14" @default.
• W2570289311 title "Targeting Menin-MLL Interaction to Inhibit MLL Fusion Oncoproteins in Leukemia" @default.
• W2570289311 doi "https://doi.org/10.1182/blood.v118.21.2497.2497" @default.
• W2570289311 hasPublicationYear "2011" @default.
• W2570289311 type Work @default.
• W2570289311 sameAs 2570289311 @default.
• W2570289311 citedByCount "1" @default.
• W2570289311 countsByYear W25702893112021 @default.
• W2570289311 crossrefType "journal-article" @default.
• W2570289311 hasAuthorship W2570289311A5008141260 @default.
• W2570289311 hasAuthorship W2570289311A5011317809 @default.
• W2570289311 hasAuthorship W2570289311A5026691889 @default.
• W2570289311 hasAuthorship W2570289311A5029035188 @default.
• W2570289311 hasAuthorship W2570289311A5044898715 @default.
• W2570289311 hasAuthorship W2570289311A5052716698 @default.
• W2570289311 hasAuthorship W2570289311A5069778809 @default.
• W2570289311 hasAuthorship W2570289311A5080373326 @default.
• W2570289311 hasAuthorship W2570289311A5080568394 @default.
• W2570289311 hasAuthorship W2570289311A5084249783 @default.
• W2570289311 hasConcept C104317684 @default.
• W2570289311 hasConcept C111829193 @default.
• W2570289311 hasConcept C123894998 @default.
• W2570289311 hasConcept C138626823 @default.
• W2570289311 hasConcept C165864922 @default.
• W2570289311 hasConcept C2778461978 @default.
• W2570289311 hasConcept C2781018059 @default.
• W2570289311 hasConcept C2909762590 @default.
• W2570289311 hasConcept C29537977 @default.
• W2570289311 hasConcept C40767141 @default.
• W2570289311 hasConcept C502942594 @default.
• W2570289311 hasConcept C54355233 @default.
• W2570289311 hasConcept C86803240 @default.
• W2570289311 hasConceptScore W2570289311C104317684 @default.
• W2570289311 hasConceptScore W2570289311C111829193 @default.
• W2570289311 hasConceptScore W2570289311C123894998 @default.
• W2570289311 hasConceptScore W2570289311C138626823 @default.
• W2570289311 hasConceptScore W2570289311C165864922 @default.
• W2570289311 hasConceptScore W2570289311C2778461978 @default.
• W2570289311 hasConceptScore W2570289311C2781018059 @default.
• W2570289311 hasConceptScore W2570289311C2909762590 @default.
• W2570289311 hasConceptScore W2570289311C29537977 @default.
• W2570289311 hasConceptScore W2570289311C40767141 @default.
• W2570289311 hasConceptScore W2570289311C502942594 @default.
• W2570289311 hasConceptScore W2570289311C54355233 @default.
• W2570289311 hasConceptScore W2570289311C86803240 @default.
• W2570289311 hasIssue "21" @default.
• W2570289311 hasLocation W25702893111 @default.
• W2570289311 hasOpenAccess W2570289311 @default.
• W2570289311 hasPrimaryLocation W25702893111 @default.
• W2570289311 hasRelatedWork W1972258126 @default.
• W2570289311 hasRelatedWork W2076085262 @default.
• W2570289311 hasRelatedWork W2085326265 @default.
• W2570289311 hasRelatedWork W2167516123 @default.
• W2570289311 hasRelatedWork W2567695862 @default.
• W2570289311 hasRelatedWork W4244240117 @default.
• W2570289311 hasRelatedWork W4249619784 @default.
• W2570289311 hasRelatedWork W4308180770 @default.
• W2570289311 hasRelatedWork W4315785610 @default.
• W2570289311 hasRelatedWork W3112414332 @default.
• W2570289311 hasVolume "118" @default.
• W2570289311 isParatext "false" @default.
• W2570289311 isRetracted "false" @default.
• W2570289311 magId "2570289311" @default.
• W2570289311 workType "article" @default.